Preliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting |
|
November 07, 2022 |
November 2022 Bond Updates
|
- Poster with updated Phase Ib TOUCH results suggest selinexor plus GemOx could provide a therapeutic option for heavily pre-treated Stage III/IV patients with relapsed/refractory (R/R) T and NK-cell lymphoma - Online abstract with results from the open-label LAUNCH study demonstrated the...
|
|
View more at: https://www.prnewswire.com:443/news-releases/preliminary-results-from-two-clinical-studies-of-selinexor-to-be-presented-at-2022-ash-annual-meeting-301669857.html
|